Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia...
22 KB (1,994 words) - 08:45, 4 November 2024
to TK inhibitors, four novel agents were later developed. The first, dasatinib, blocks several further oncogenic proteins, in addition to more potent...
34 KB (3,877 words) - 13:44, 25 October 2024
except for T315I. Dasatinib is also not a substrate of multidrug P-glycoprotein efflux pumps like imatinib. Because of this dasatinib may be active in...
56 KB (6,470 words) - 20:27, 19 November 2024
sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib...
5 KB (232 words) - 10:23, 8 March 2024
are repurposed anti-cancer molecules, such as the chemotherapeutic drug dasatinib and the experimental small molecule navitoclax. Soluble urokinase plasminogen...
26 KB (2,027 words) - 18:28, 24 December 2024
D+Q may refer to: Dasatinib#Dasatinib+Quercetin Drawn & Quarterly This disambiguation page lists articles associated with the title D+Q. If an internal...
231 bytes (42 words) - 03:27, 19 December 2023
alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib. Experimental therapies under investigation include endothelin receptor...
38 KB (3,337 words) - 22:36, 4 January 2025
Agonists: Ancestim Stem cell factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
121 KB (13,818 words) - 07:04, 26 December 2024
are point-mutations in the kinase of BCR-abl. New inhibitors include dasatinib and nilotinib, which are significantly more potent than imatinib and may...
29 KB (3,538 words) - 15:01, 5 December 2023
2006: FDA Approval of Dasatinib and Nilotinib for Resistant Leukemia MD Anderson researchers demonstrate the efficacy of dasatinib and nilotinib, leading...
55 KB (5,295 words) - 00:12, 6 January 2025
kinases) have been developed for therapeutic use. One notable example is dasatinib which has been approved for the treatment of chronic myeloid leukemia...
21 KB (2,648 words) - 12:12, 26 July 2024
(Eli Lilly and Company) darifenacin hydrochloride (USAN) Darzalex Faspro dasatinib (USAN, INN) datelliptium chloride (INN) DaTSCAN (GE Healthcare) Daunorubicin...
6 KB (331 words) - 04:31, 10 November 2024
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
22 KB (1,737 words) - 00:12, 27 December 2024
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
66 KB (6,684 words) - 19:26, 2 December 2024
T315I) and some dasatinib resistant mutations. Bafetinib also has more affinity for Bcr-Abl than nilotinib (but less than dasatinib) but only targets...
8 KB (733 words) - 11:36, 12 August 2023
Agonists: Ancestim Stem cell factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
149 KB (15,719 words) - 16:46, 9 December 2024
symptoms. Among currently available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST)...
44 KB (5,283 words) - 12:50, 27 December 2024
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
83 KB (7,404 words) - 21:59, 23 November 2024
Agonists: Ancestim Stem cell factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
73 KB (6,489 words) - 08:56, 21 December 2024
Agonists: Ancestim Stem cell factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
13 KB (1,177 words) - 01:44, 4 November 2024
Agonists: Ancestim Stem cell factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
92 KB (8,680 words) - 16:40, 7 January 2025
leukemia (CML) and later gefitinib and erlotinib aiming at the EGF receptor. Dasatinib is a Src tyrosine kinase inhibitor that is effective both as a senolytic...
10 KB (1,179 words) - 18:31, 8 August 2024
replaced gefitinib in this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib...
20 KB (2,234 words) - 01:21, 22 July 2024
agents. PP1, PP2 (kinase inhibitor) are both inhibitors of Lck and FynT. Dasatinib Rivera-Torres J, José ES (2019). "Src Tyrosine Kinase Inhibitors: New...
3 KB (332 words) - 14:43, 20 November 2023
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
28 KB (2,876 words) - 17:53, 7 January 2025
Additionally, tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are incorporated for Philadelphia chromosome-positive ALL, improving treatment...
80 KB (7,799 words) - 16:17, 2 January 2025
due to drug or toxin exposures. Methamphetamines, the chemotherapeutic dasatinib and the appetite suppressant and diet drug fenfluramine are associated...
23 KB (2,753 words) - 03:42, 16 September 2024
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
4 KB (226 words) - 09:18, 22 August 2024
pyrimidinylpiperazine derivatives are drugs, including: Buspirone – anxiolytic Dasatinib – anticancer agent Eptapirone – anxiolytic Gepirone – anxiolytic Ipsapirone –...
7 KB (520 words) - 13:23, 12 March 2024
Meclozine MT-45 Oxatomide SNC-80 Vanoxerine Pyrimidinylpiperazines Buspirone Dasatinib Eptapirone Gepirone Ipsapirone Piribedil Pyrimidinylpiperazine Revospirone...
10 KB (814 words) - 04:38, 1 August 2024